AllSight
Companies · IMMX · Pharmaceutical Preparations

Immix Biopharma, Inc. (IMMX)

Immix Biopharma, Inc. (IMMX) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Immix Biopharma, Inc. (IMMX) stock — financials & valuation

Key numbers for Immix Biopharma, Inc. (IMMX): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 41/100 — a percentile rank of Immix Biopharma, Inc.’s fundamentals against Manufacturing peers, weakest on growth. A quality ranking, not a price prediction.

Market cap$744.7M
EV / EBITDA-12.5×
Return on equity-17.4%
ROIC-1222.1%
Debt / equity0.0×
Dividend yield0.0%

Is Immix Biopharma, Inc. overvalued? P/B looks fair vs its 5-year range.

Independent of the events above — derived from Immix Biopharma, Inc.’s own financial statements and shown as context, never as advice.

Sep 30, 2026$125M equity financing
Immix Biopharma launches $125M stock offering as NXC-201 advances
Sep 29, 2026At the bar
Immix Biopharma clinical results show 89% CR rate as full cohort expands
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact